CN101461774A - Oral liquid containing trimetazidine dihydrochloride and preparation method thereof - Google Patents
Oral liquid containing trimetazidine dihydrochloride and preparation method thereof Download PDFInfo
- Publication number
- CN101461774A CN101461774A CN 200710179834 CN200710179834A CN101461774A CN 101461774 A CN101461774 A CN 101461774A CN 200710179834 CN200710179834 CN 200710179834 CN 200710179834 A CN200710179834 A CN 200710179834A CN 101461774 A CN101461774 A CN 101461774A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- liquid according
- trimetazidine hydrochloride
- preparation
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses oral liquid containing Trimetazidine Dihydrochloride. The recipe comprises Trimetazidine Dihydrochloride and other supplementary materials. The pH value of the oral liquid is between 6.5 and 8.5. The oral liquid is mainly used for the preventative treatment of angina pectoris attacks and the supplementary expectant treatment of vertigo and tinnitus.
Description
Technical field
The present invention relates to a kind of Trimetazidine Hydrochloride oral liquid, especially pH value and be 6.5～8.5 Trimetazidine Hydrochloride oral liquid.
Background technology
Trimetazidine is a kind of important drugs in the metabolism therapy of resisting myocardial ischemia, it is mainly by suppressing fatty acids metabolism, promoting glucose metabolism and aerobic oxidation to increase the generation of cardiac energy, be used for the treatment of angina pectoris, ischemic cardiomyopathy etc. at present, have clinical efficacy significantly, can share with other drug, advantage such as untoward reaction is little.
The dosage form of having gone on the market has a variety of, and CN1166408C has related to the substrate tablet that can discharge trimetazidine behind a kind of oral administration for a long time.CN1994280A discloses a kind of sustained-release micro-pellet of trimetazidine and preparation method thereof.CN1864680A has related to a kind of oral disintegrating tablet of trimetazidine and preparation method thereof.But what above-mentioned technology prepared all is solid preparation, and diseases such as angina pectoris belong to acute disease, needs medicine onset rapidly in time.Use solid preparation, taken certain difficulty when patient's disease is sent out, and onset is relatively slow, increase patient's misery.
Research worker is found, Trimetazidine Hydrochloride is prepared into oral liquid, taking convenience when patient's disease is sent out, and also rapid-action, can alleviate slight illness in the short period of time, improve compliance of patients.And the present technique preparation is simple, and the technology favorable reproducibility can also reduce production costs greatly.So the invention provides a kind of Trimetazidine Hydrochloride oral liquid and preparation technology thereof.
Summary of the invention
The invention provides a kind of oral liquid, be specifically related to a kind of oral liquid that Trimetazidine Hydrochloride and its acceptable accessories prepare that contains, allevating angina pectoris patient's misery rapidly, preparation technology is simple, the low and technology favorable reproducibility of cost.
The invention provides the oral liquid of the complementary symptomatic treatment of a kind of prophylactic treatment that is used for angina pectoris attacks and dizzy and tinnitus, its active component is a Trimetazidine Hydrochloride.
This oral liquid provided by the invention, its pH value are 6.5～8.5.
This oral liquid provided by the invention, its pH regulator agent is a sodium hydroxide.
This oral liquid provided by the invention, the percentage by weight of Trimetazidine Hydrochloride are 5～60%, preferred 10～30%.
This oral liquid provided by the invention, its antiseptic are one or more the mixture in benzoic acid, sorbic acid, the methyl hydroxybenzoate.
This oral liquid provided by the invention, its correctives are one or more the mixture in green apple powdered flavor, Fructus Citri tangerinae powdered flavor, Mentholum, the mannitol.
The specific embodiment
The present invention is described in further detail below in conjunction with embodiment, but be not limited to following embodiment.Wherein " % " is meant " percentage by weight ".
Embodiment 1
Preparation method: the Trimetazidine Hydrochloride and mannitol, the methyl hydroxybenzoate that take by weighing the prescription ratio are dissolved in an amount of purified water, stirring is fully dissolved it, and it is about 7.2 that the sodium hydrate aqueous solution with 1% is regulated pH value, uses the purified water standardize solution, cross 0.45 μ m filter membrane, fill.
Embodiment 2
Preparation method: the Trimetazidine Hydrochloride and green apple powdered flavor, the benzoic acid that take by weighing the prescription ratio are dissolved in an amount of purified water, stirring is fully dissolved it, and it is about 7.2 that the sodium hydrate aqueous solution with 0.5% is regulated pH value, uses the purified water standardize solution, cross 0.45 μ m filter membrane, fill.
Embodiment 3
Preparation method: the Trimetazidine Hydrochloride and Mentholum, the sorbic acid that take by weighing the prescription ratio are dissolved in an amount of purified water, stirring is fully dissolved it, and it is about 7.2 that the sodium hydrate aqueous solution with 2% is regulated pH value, uses the purified water standardize solution, cross 0.45 μ m filter membrane, fill.
Claims (7)
1. one kind is used for the treatment of prevention angina pectoris, dizzy and tinnitus Trimetazidine Hydrochloride oral liquid, it is characterized in that pH value is 6.5～8.5.
2. oral liquid according to claim 1 is characterized in that with the sodium hydroxide being the pH regulator agent.
3. oral liquid according to claim 1, the percentage by weight that it is characterized in that Trimetazidine Hydrochloride is 10～30%.
4. oral liquid according to claim 1 is characterized in that containing one or more mixture in benzoic acid, sorbic acid, the methyl hydroxybenzoate as antiseptic.
5. oral liquid according to claim 1 is characterized in that containing one or more mixture in green apple powdered flavor, Fructus Citri tangerinae powdered flavor, Mentholum, the mannitol as correctives.
6. the described oral liquid of root claim 1 is made up of Trimetazidine Hydrochloride 15.0%, purified water 79.9%, Mentholum 5.00%, sorbic acid 0.10%.
7. the preparation method of oral liquid according to claim 6 is characterized in that may further comprise the steps:
(1) Trimetazidine Hydrochloride and Mentholum, the sorbic acid that takes by weighing the prescription ratio is dissolved in an amount of purified water, stirs it is fully dissolved;
(2) regulating pH value with 2% sodium hydrate aqueous solution is about 7.2;
(3) use the purified water standardize solution, cross 0.45 μ m filter membrane, fill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710179834 CN101461774A (en) | 2007-12-19 | 2007-12-19 | Oral liquid containing trimetazidine dihydrochloride and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710179834 CN101461774A (en) | 2007-12-19 | 2007-12-19 | Oral liquid containing trimetazidine dihydrochloride and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101461774A true CN101461774A (en) | 2009-06-24 |
Family
ID=40802711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710179834 Pending CN101461774A (en) | 2007-12-19 | 2007-12-19 | Oral liquid containing trimetazidine dihydrochloride and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101461774A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3755329A4 (en) * | 2018-02-19 | 2021-10-27 | Martin Pharmaceuticals, Inc. | Stable oral liquid formulation of trimetazidine |
-
2007
- 2007-12-19 CN CN 200710179834 patent/CN101461774A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3755329A4 (en) * | 2018-02-19 | 2021-10-27 | Martin Pharmaceuticals, Inc. | Stable oral liquid formulation of trimetazidine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016145910A1 (en) | Application of nadh and nmn in preparation of parkinson's disease drug or health care product | |
| BG104568A (en) | Pharmaceutical compositions containing sibutramine and orlistat | |
| CN101990427A (en) | Combination of mitiglinide and metformin and process for preparing same | |
| RU2535019C1 (en) | Sedative and spasmolytic agent | |
| CN102319225B (en) | Trimetazidine hydrochloride sustained release tablet and preparation method thereof | |
| CN101474166B (en) | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof | |
| CN100366247C (en) | Single nitrate isosorbide delayed-release tablets | |
| CN101461774A (en) | Oral liquid containing trimetazidine dihydrochloride and preparation method thereof | |
| CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
| CN106667903A (en) | Fluoxetine tincture for treating leucoderma | |
| CN102671200A (en) | Isomaltose hypgather tablet excipient, medicine tablet and preparation method | |
| CN102698280B (en) | Tagatose tablet excipient, medicinal tablet and preparation method of medicinal tablet | |
| CN101455668A (en) | Preparation of trimetazidine hydrochloride sustained-release tablets and use thereof | |
| CN101125147B (en) | Glucosamine calcium medicine preparation, preparation method and application thereof | |
| CA2408920A1 (en) | Methods for prevention of ulcers and improving physiological performance | |
| RU2009121838A (en) | ORAL DOSAGE FORM CONTAINING COMPOUNDS OF TRIZOMISED GLYCERINE | |
| KR20070116087A (en) | The use of hydrochloric acid for the manufacture of medicament for the treatment of hypertension | |
| CN103405471A (en) | Compound preparation containing ilaprazole sodium | |
| CN101869562B (en) | Levamlodipine compound medicinal preparation | |
| CN1309376C (en) | Musk slow-controlled release preparation and preparation method thereof | |
| CN101904847A (en) | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs | |
| CN104825386A (en) | Epidermal anesthesia gel and preparation method thereof | |
| CN101444521B (en) | Pharmaceutical preparation containing alendronate sodium and cholecalciferol-cholesterol | |
| JP2007137896A (en) | Ibuprofen-containing pharmaceutical preparation | |
| CN100375612C (en) | Blood pressure lowering dripping pills with chryanthemum flower and pearl and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: AVENTIS PHARMA (HAI NAN) CO., LTD. Free format text: FORMER OWNER: DEZHONG WANQUAN PHARMACEUTICALS TECH. DEV. CO., LTD., BEIJING Effective date: 20110713 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100097 WANQUAN BUILDING, NO. 3, JINZHUANG, SIJIQING, HAIDIAN DISTRICT, BEIJING TO: 570314 NO. 279, NANHAI AVENUE, HAIKOU CITY |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110713 Address after: 570314 No. 279 Nanhai Road, Haikou Applicant after: Beijing D-Venturepharm Technology Development Co., Ltd. Address before: 100097 Beijing city Haidian District Sijiqing Wanquan Zhuang 3 Building Applicant before: Dezhong Wanquan Pharmaceuticals Tech. Dev. Co., Ltd., Beijing |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090624 |